VolitionRx's (VNRX) "Buy" Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of VolitionRx (NYSE:VNRX - Free Report) in a research note published on Wednesday morning,Benzinga reports. They currently have a $5.00 target price on the stock.

VNRX has been the topic of several other research reports. HC Wainwright began coverage on VolitionRx in a report on Tuesday, April 8th. They issued a "buy" rating and a $2.50 price objective on the stock. Jones Trading upgraded VolitionRx to a "strong-buy" rating and set a $3.00 price target on the stock in a report on Tuesday, June 10th. Finally, Wall Street Zen began coverage on VolitionRx in a report on Thursday, May 15th. They set a "sell" rating on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $3.50.

VolitionRx Price Performance

Shares of VNRX stock traded down $0.04 on Wednesday, hitting $0.66. The stock had a trading volume of 166,366 shares, compared to its average volume of 207,551. The firm has a market capitalization of $68.10 million, a P/E ratio of -1.84 and a beta of 1.20. VolitionRx has a 1 year low of $0.40 and a 1 year high of $0.94. The company's 50 day moving average price is $0.60 and its 200-day moving average price is $0.58.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Two Sigma Securities LLC acquired a new position in shares of VolitionRx during the 4th quarter worth about $29,000. Millennium Management LLC acquired a new position in shares of VolitionRx during the 4th quarter worth about $36,000. Northern Trust Corp boosted its position in shares of VolitionRx by 32.0% during the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company's stock worth $71,000 after acquiring an additional 28,579 shares in the last quarter. Silverberg Bernstein Capital Management LLC boosted its position in shares of VolitionRx by 42.8% during the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company's stock worth $153,000 after acquiring an additional 60,209 shares in the last quarter. Finally, Lagoda Investment Management L.P. raised its stake in VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock worth $4,546,000 after acquiring an additional 1,481,000 shares in the last quarter. 8.09% of the stock is owned by institutional investors and hedge funds.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.